Serum uric acid levels and multiple health outcomes: Umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Li, Xue ^a   Meng, Xiangrui ^a   Timofeeva, Maria ^b   Tzoulaki, Ioanna ^c   Tsilidis, Konstantinos K ^c,d   Ioannidis, P A ^e,f   Campbell, Harry ^a   Theodoratou, Evropi ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF IOANNINA   (Greece)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DISORDERS OF HIGHER CEREBRAL FUNCTION; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASM; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; MORTALITY; NEPHROLITHIASIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; BLOOD; GOUT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOMARKERS; GOUT; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; NEPHROLITHIASIS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URIC ACID;

EID: 85020442980     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2376     Document Type: Review

References (147)

1. Garrod AB. Observations on certain pathological conditions of the blood and urine, in gout, rheumatism, and Bright's disease. Med Chir Trans 1848;31:83-97. doi:10.1177/095952874803100109.
2. Davis NS Jr. The cardio-vascular and renal relations and manifestations of gout. JAMA 1897;XXIX:261-2doi:10.1001/jama.1897.02440320005001a.
3. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141:637-44. doi:10.1093/oxfordjournals.aje.a117479.
4. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. doi:10.7326/0003-4819-131-1-199907060-00003.
5. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997;78:147-53. doi:10.1136/hrt.78.2.147.
6. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate. Ann Intern Med 1999;131:62-3. doi:10.7326/0003-4819-131-1-199907060-00012.
7. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21. doi:10.1056/NEJMra0800885.
8. Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46. doi:10.1002/acr.21772.
9. Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Semin Arthritis Rheum 2016.
10. Nakagawa T, Kang DH, Feig D, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006;69:1722-5. doi:10.1038/sj.ki.5000391.
11. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?Curr Hypertens Rep 2013;15:175-81. doi:10.1007/s11906-013-0344-5.
12. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009;5:265-72. doi:10.2147/VHRM.S4265.
13. Meotti FC, Jameson GN, Turner R, et al. Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 2011;286:12901-11. doi:10.1074/jbc.M110.172460.
14. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-31. doi:10.1152/ajprenal.00140.2005.
15. Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders - facts and controversies. Biochem Med (Zagreb) 2012;22:63-75. doi:10.11613/BM.2012.007.
16. Alvarez-Lario B, Macarrón-Vicente J. Is there anything good in uric acid?QJM 2011;104:1015-24. doi:10.1093/qjmed/hcr159.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2.
18. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172:137-59. doi:10.1111/j.1467-985X.2008.00552.x.
19. Higgins JP. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008;37:1158-60. doi:10.1093/ije/dyn204.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. doi:10.1136/bmj.315.7109.629.
21. Ioannidis JP. Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 2011;68:773-80. doi:10.1001/archgenpsychiatry.2011.28.
22. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials 2007;4:245-53. doi:10.1177/1740774507079441.
23. Ioannidis JPA. Clarifications on the application and interpretation of the test for excess significance and its extensions. J Math Psychol 2013;57:184-7doi:10.1016/j.jmp.2013.03.002.
24. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000;19:3127-31. doi:10.1002/1097-0258(20001130)19:22〈3127::AID-SIM784〉3.0.CO;2-M.
25. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42:1497-501. doi:10.1093/ije/dyt179.
26. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord 2016;23:1-9. doi:10.1016/j.parkreldis.2015.12.008.
27. Kavanagh BP. The GRADE system for rating clinical guidelines. PLoS Med 2009;6:e1000094. doi:10.1371/journal.pmed.1000094.
28. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011;40:740-52. doi:10.1093/ije/dyq151.
29. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?Am J Med 2005;118:816-26. doi:10.1016/j.amjmed.2005.03.043.
30. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk?Nutr Metab Cardiovasc Dis 2007;17:409-14. doi:10.1016/j.numecd.2007.02.011.
31. Barron E, Lara J, White M, Mathers JC. Blood-borne biomarkers of mortality risk: systematic review of cohort studies. PLoS One 2015;10:e0127550. doi:10.1371/journal.pone.0127550.
32. Dimitroula HV, Hatzitolios AI, Karvounis HI. The role of uric acid in stroke: the issue remains unresolved. Neurologist 2008;14:238-42. doi:10.1097/NRL.0b013e31815c666b.
33. Hwu CM, Lin KH. Uric acid and the development of hypertension. Med Sci Monit 2010;16:RA224-30.
34. Avram Z, Krishnan E. Hyperuricaemia - where nephrology meets rheumatology. Rheumatology (Oxford) 2008;47:960-4. doi:10.1093/rheumatology/ken070.
35. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease?Curr Opin Nephrol Hypertens 2009;18:526-30. doi:10.1097/MNH.0b013e328330d9d0.
36. Alonso A, Sovell KA. Gout, hyperuricemia, and Parkinson's disease: a protective effect?Curr Rheumatol Rep 2010;12:149-55. doi:10.1007/s11926-010-0083-4.
37. Chang YT, Chang WN, Tsai NW, et al. The roles of biomarkers of oxidative stress and antioxidant in Alzheimer's disease: a systematic review. Biomed Res Int 2014;2014:182303. doi:10.1155/2014/182303.
38. Cnossen JS, de Ruyter-Hanhijärvi H, van der Post JA, Mol BW, Khan KS, ter Riet G. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2006;85:519-25. doi:10.1080/00016340500342037.
39. Zhang CH, Huang DS, Shen D, et al. Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk. Cell Physiol Biochem 2016;38:1589-95. doi:10.1159/000443099.
40. Zhao J, Liu T, Korantzopoulos P, et al. Association between serum uric acid and atrial fibrillation recurrence following catheter ablation: A meta-analysis. Int J Cardiol 2016;204:103-5. doi:10.1016/j.ijcard.2015.11.167.
41. Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep 2016;6:19520. doi:10.1038/srep19520.
42. Qin T, Zhou X, Wang J, et al. Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich) 2016;18:1268-78. doi:10.1111/jch.12855.
43. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014;16:15-24. doi:10.1093/eurjhf/hft132.
44. Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One 2014;9:e114259. doi:10.1371/journal.pone.0114259.
45. Jiang M, Gong D, Fan Y. Serum uric acid levels and risk of prehypertension: a meta-analysis. Clin Chem Lab Med 2016.
46. Song X, Wang Y, Hou X, et al. Association between hyperuricemia and clinical adverse outcomes after percutaneous coronary intervention: A meta-analysis. Int J Cardiol 2015;201:658-62. doi:10.1016/j.ijcard.2015.07.074.
47. Trkulja V, Car S. On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies. Croat Med J 2012;53:162-72. doi:10.3325/cmj.2012.53.162.
48. Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis 2014;232:265-70. doi:10.1016/j.atherosclerosis.2013.11.051.
49. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737-42. doi:10.2337/dc09-0288.
50. Jia Z, Zhang X, Kang S, Wu Y. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract 2013;101:88-96. doi:10.1016/j.diabres.2013.03.026.
51. Xu Y, Zhu J, Gao L, et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One 2013;8:e78206. doi:10.1371/journal.pone.0078206.
52. Xu X, Du N, Wang R, Wang Y, Cai S. Hyperuricemia is independently associated with increased risk of atrial fibrillation: A meta-analysis of cohort studies. Int J Cardiol 2015;184:699-702. doi:10.1016/j.ijcard.2015.02.038.
53. Yu S, Chen Y, Hou X, et al. Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis. Mol Neurobiol 2016;53:1045-51. doi:10.1007/s12035-014-9075-0.
54. Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One 2014;9:e100801. doi:10.1371/journal.pone.0100801.
55. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 2014;15:122. doi:10.1186/1471-2369-15-122.
56. Huang Y, Li YL, Huang H, Wang L, Yuan WM, Li J. Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies. PLoS One 2012;7:e39457. doi:10.1371/journal.pone.0039457.
57. Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol 2016;53:2594-9. doi:10.1007/s12035-015-9271-6.
58. Khan A. T JQ, Dawson J. Serum uric acid level and cognitive function; A systematic review and meta-analysis. Cerebrovasc Dis 2013;35:821.
59. Shen C, Guo Y, Luo W, Lin C, Ding M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 2013;40:73-9. doi:10.1017/S0317167100012981.
60. Wang L, Hu W, Wang J, Qian W, Xiao H. Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. Mult Scler Relat Disord 2016;9:17-22. doi:10.1016/j.msard.2016.05.008.
61. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014;261:1133-8. doi:10.1007/s00415-014-7331-x.
62. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013;74:400-9. doi:10.1016/j.biopsych.2013.03.018.
63. Bartoli F, Crocamo C, Mazza MG, Clerici M, Carrà G. Uric acid levels in subjects with bipolar disorder: A comparative meta-analysis. J Psychiatr Res 2016;81:133-9. doi:10.1016/j.jpsychires.2016.07.007.
64. Yan S, Zhang P, Xu W, et al. Serum Uric Acid Increases Risk of Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. Mediators Inflamm 2015;2015:764250. doi:10.1155/2015/764250.
65. Zhao G. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: A meta-analysis of prospective studies. Cardiology (Switzerland) 2014;129:47.
66. Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism 2016;65:1326-41. doi:10.1016/j.metabol.2016.05.009.
67. Tamariz L, Harzand A, Verma S, Jones J, Hare J. Uric acid as a predictor of mortality in congestive heart failure: A meta-analysis. J Am Coll Cardiol 2009;53:A169.
68. Yan L, Liu Z, Zhang C. Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis. Cell Biochem Biophys 2014;70:1597-601. doi:10.1007/s12013-014-0101-7.
69. Wang Z, Lin Y, Liu Y, et al. Serum Uric Acid Levels and Outcomes After Acute Ischemic Stroke. Mol Neurobiol 2016;53:1753-9. doi:10.1007/s12035-015-9134-1.
70. Li X, Miao X, Wang H, et al. Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2016;95:e3676. doi:10.1097/MD.0000000000003676.
71. Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem 2016;49:636-42. doi:10.1016/j.clinbiochem.2015.12.010.
72. Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia (HUA) as an independent risk factor for coronary heart disease (CHD) in the general population: A systematic review and meta-analysis. ?. Clin Chem Lab Med 2015;53:S1199.
73. Chen X, Guo X, Huang R, Chen Y, Zheng Z, Shang H. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One 2014;9:e94084. doi:10.1371/journal.pone.0094084.
74. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102-10. doi:10.1002/acr.20344.
75. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92. doi:10.1002/art.24612.
76. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170-80.
77. Li YL, Wang L, Li J, Huang Y, Yuan WM. [The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies]. Zhonghua Nei Ke Za Zhi 2011;50:555-61.
78. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012;34:163-71.
79. Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 2013;8:e56864. doi:10.1371/journal.pone.0056864.
80. Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 2013;59:100-10. doi:10.1016/j.nbd.2013.07.005.
81. Shen L, Ji HF. Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis. BMJ Open 2013;3:e003620. doi:10.1136/bmjopen-2013-003620.
82. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2014;11:1102-8. doi:10.1016/j.hrthm.2014.04.003.
83. Wheeler JG, Juzwishin KDM, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155 084 controls: Prospective study and meta-analysis. PLoS Med 2005;2(3):0236-43.
84. Yang Y, Fan Y, Li J, et al. Serum uric acid as a predictor for cardiovascular and all-cause mortality in women versus men. Int J Cardiol 2015;185:125-8. doi:10.1016/j.ijcard.2015.03.121.
85. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009;55:2026-34. doi:10.1373/clinchem.2009.124891.
86. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535-43. doi:10.7326/0003-4819-158-7-201304020-00005.
87. Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr 2013;23:389-96. doi:10.1053/j.jrn.2012.08.005.
88. Zhang YF, He F, Ding HH, et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2014;34:476-81. doi:10.1007/s11596-014-1302-4.
89. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant 2014;29:406-13. doi:10.1093/ndt/gft378.
90. Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cerebrovascular and cardiovascular disease: A systematic review and meta-analysis. Cerebrovasc Dis 2010;29:321.
91. Kanbay M, Siriopol D, Nistor I, et al. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol 2014;39:348-56. doi:10.1159/000360609.
92. Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev 2012;(7):CD006817. doi:10.1002/14651858.CD006817.pub3
93. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013;15:435-42. doi:10.1111/j.1751-7176.2012.00701.x.
94. Korostishevsky M, Steves CJ, Malkin I, Spector T, Williams FM, Livshits G. Genomics and metabolomics of muscular mass in a community-based sample of UK females. Eur J Hum Genet 2016;24:277-83. doi:10.1038/ejhg.2015.85.
95. Lyngdoh T, Vuistiner P, Marques-Vidal P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 2012;7:e39321. doi:10.1371/journal.pone.0039321.
96. White J, Sofat R, Hemani G, et al. International Consortium for Blood Pressure (ICBP) UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2016;4:327-36. doi:10.1016/S2213-8587(15)00386-1.
97. Dalbeth N, Topless R, Flynn T, Cadzow M, Bolland MJ, Merriman TR. Mendelian randomization analysis to examine for a causal effect of urate on bone mineral density. J Bone Miner Res 2015;30:985-91. doi:10.1002/jbmr.2434.
98. Xiong A, Yao Q, He J, Fu W, Yu J, Zhang Z. No causal effect of serum urate on bone-related outcomes among a population of postmenopausal women and elderly men of Chinese Han ethnicity - a Mendelian randomization study. Osteoporos Int 2016;27:1031-9. doi:10.1007/s00198-015-3341-5.
99. Kleber ME, Delgado G, Grammer TB, et al. Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. J Am Soc Nephrol 2015;26:2831-8. doi:10.1681/ASN.2014070660.
100. Keenan T, Zhao W, Rasheed A, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol 2016;67:407-16. doi:10.1016/j.jacc.2015.10.086.
101. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262. doi:10.1136/bmj.f4262.
102. Oikonen M, Wendelin-Saarenhovi M, Lyytikäinen LP, et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. Atherosclerosis 2012;223:497-503. doi:10.1016/j. atherosclerosis.2012.05.036.
103. Yan D, Wang J, Jiang F, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. Int J Cardiol 2016;214:194-9. doi:10.1016/j.ijcard.2016.03.206.
104. Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study. Am J Kidney Dis 2015;65:294-302. doi:10.1053/j.ajkd.2014.07.021.
105. Sluijs I, Holmes MV, van der Schouw YT, et al. InterAct Consortium. A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. Diabetes 2015;64:3028-36. doi:10.2337/db14-0742.
106. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523-30. doi:10.1161/CIRCGENETICS.109.934455.
107. Dai X, Yuan J, Yao P, et al. Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. Eur J Epidemiol 2013;28:669-76. doi:10.1007/s10654-013-9829-4.
108. Greenberg KI, McAdams-DeMarco MA, Köttgen A, Appel LJ, Coresh J, Grams ME. Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol 2015;10:776-83. doi:10.2215/CJN.05870614.
109. Testa A, Mallamaci F, Spoto B, et al. Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clin J Am Soc Nephrol 2014;9:1059-65. doi:10.2215/CJN.11041013.
110. Hughes K, Flynn T, de Zoysa J, Dalbeth N, Merriman TR. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int 2014;85:344-51. doi:10.1038/ki.2013.353.
111. Gao J, Xu H, Huang X, Chen H. Short communication: genetic variations of SLC2A9 in relation to Parkinson's disease. Transl Neurodegener 2013;2:5. doi:10.1186/2047-9158-2-5.
112. Facheris MF, Hicks AA, Minelli C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011;43:246-50. doi:10.1007/s12031-010-9409-y.
113. Lyngdoh T, Bochud M, Glaus J, et al. Associations of serum uric acid and SLC2A9 variant with depressive and anxiety disorders: a population-based study. PLoS One 2013;8:e76336. doi:10.1371/journal.pone.0076336.
114. Houlihan LM, Wyatt ND, Harris SE, et al. Variation in the uric acid transporter gene (SLC2A9) and memory performance. Hum Mol Genet 2010;19:2321-30. doi:10.1093/hmg/ddq097.
115. Burgess S, Daniel RM, Butterworth AS, Thompson SG. EPIC-InterAct Consortium. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol 2015;44:484-95. doi:10.1093/ije/dyu176.
116. González-Aramburu I, Sánchez-Juan P, Jesús S, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 2013;28:1737-40. doi:10.1002/mds.25507.
117. González-Aramburu I, Sánchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20:637-9. doi:10.1016/j.parkreldis.2014.02.023.
118. Han X, Gui L, Liu B, et al. Associations of the uric acid related genetic variants in SLC2A9 and ABCG2 loci with coronary heart disease risk. BMC Genet 2015;16:4. doi:10.1186/s12863-015-0162-7.
119. Mallamaci F, Testa A, Leonardis D, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens 2014;32:1621-8, discussion 1628. doi:10.1097/HJH.0000000000000224.
120. McKeigue PM, Campbell H, Wild S, et al. Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization'): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol 2010;39:907-18. doi:10.1093/ije/dyp397.
121. Parsa A, Brown E, Weir MR, et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 2012;81:502-7. doi:10.1038/ki.2011.414.
122. Pfister R, Barnes D, Luben R, et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia 2011;54:2561-9. doi:10.1007/s00125-011-2235-0.
123. Rasheed H, Hughes K, Flynn TJ, Merriman TR. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ Cardiovasc Genet 2014;7:830-7. doi:10.1161/CIRCGENETICS.114.000556.
124. Sedaghat S, Pazoki R, Uitterlinden AG, et al. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension 2014;64:1061-6. doi:10.1161/HYPERTENSIONAHA.114.03757.
125. Simon KC, Eberly S, Gao X, et al. Parkinson Study Group. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol 2014;76:862-8. doi:10.1002/ana.24281.
126. Stark K, Reinhard W, Grassl M, et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 2009;4:e7729. doi:10.1371/journal.pone.0007729.
127. Sun X, Zhang R, Jiang F, et al. Common variants related to serum uric acid concentrations are associated with glucose metabolism and insulin secretion in a Chinese population. PLoS One 2015;10:e0116714. doi:10.1371/journal.pone.0116714.
128. Tabara Y, Kohara K, Kawamoto R, et al. Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study. Am J Nephrol 2010;32:279-86. doi:10.1159/000318943.
129. Voruganti VS, Franceschini N, Haack K, et al. Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians. Eur J Hum Genet 2014;22:938-43. doi:10.1038/ejhg.2013.264.
130. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009;266:558-70. doi:10.1111/j.1365-2796.2009.02133.x.
131. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol 2001;17:1097-104. doi:10.1023/A:1021216713504.
132. Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013;52:127-34. doi:10.1093/rheumatology/kes223.
133. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009;61:225-32. doi:10.1002/art.24164.
134. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions - agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010;63:513-23. doi:10.1016/j.jclinepi.2009.03.009.
135. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035. doi:10.1136/bmj.g2035.
136. Belbasis L, Savvidou MD, Kanu C, Evangelou E, Tzoulaki I. Birth weight in relation to health and disease in later life: an umbrella review of systematic reviews and meta-analyses. BMC Med 2016;14:147. doi:10.1186/s12916-016-0692-5.
137. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. Am J Med 2012;125:499-504. doi:10.1016/j.amjmed.2011.11.010.
138. Köttgen A, Albrecht E, Teumer A, et al. LifeLines Cohort Study CARDIoGRAM Consortium DIAGRAM Consortium ICBP Consortium MAGIC Consortium. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;45:145-54. doi:10.1038/ng.2500.
139. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42. doi:10.1136/annrheumdis-2016-209707.
140. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064-9. doi:10.1093/aje/kwp033.
141. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-7. doi:10.1093/aje/kwm127.
142. Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-8. doi:10.1002/gps.1469.
143. Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. J Pediatr 2013;162:896-902. doi:10.1016/j.jpeds.2012.12.078.
144. Tamariz L, Hare JM. Xanthine oxidase inhibitors in heart failure: where do we go from here?Circulation 2015;131:1741-4. doi:10.1161/CIRCULATIONAHA.115.016379.
145. Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q 2016;94:485-514. doi:10.1111/1468-0009.12210.
146. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: an empirical assessment. PLoS Med 2007;4:e79. doi:10.1371/journal.pmed.0040079.
147. Ioannidis JP. Exposure-wide epidemiology: revisiting Bradford Hill. Stat Med 2016;35:1749-62. doi:10.1002/sim.6825.